docetaxel anhydrous has been researched along with nimbolide in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (nimbolide) | Trials (nimbolide) | Recent Studies (post-2010) (nimbolide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 95 | 0 | 75 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Alharbi, SA; Chinnathambi, A; Deivasigamani, A; Hui, KM; Jung, YY; Mohan, CD; Rangappa, KS; Sethi, G; Zhang, J | 1 |
1 other study(ies) available for docetaxel anhydrous and nimbolide
| Article | Year |
|---|---|
Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-κB signaling pathway in prostate cancer preclinical models.
Topics: Cell Line, Tumor; DNA; Docetaxel; Humans; Limonins; Male; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survivin | 2022 |